Highly anticipated trial data comparing mechanical thrombectomy to anticoagulation alone for intermediate- and high-risk pulmonary embolism showed that the more aggressive strategy improved outcomes.
"We need telehealth the way we had it for COVID," Cathie Biga told Cardiovascular Business at TCT 2025. "We don't want to go back to having it so restricted."
B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more.
Nee Khoo, MBChB, director of the echocardiography lab at Canada's Stollery Children’s Hospital, explains the rapid adoption of pediatric 3D transesophageal echo.
Beyond amyloidosis, nuclear cardiology is also increasingly used to image inflammation and infection in the myocardium, especially in diseases such as cardiac sarcoidosis and myocarditis.
Renee Bullock-Palmer, MD, director, non-invasive cardiac imaging, at the Deborah Heart and Lung Center, explains CT calcium scoring can determine if a patient needs to take aspirin and statins for prevention of coronary disease.
Rad Partners' Nina Kottler, MD, explains what practices should consider when assessing artificial intelligence solutions in an era where there is little reimbursement.
Michael Bruno, MD, vice chair for quality and patient safety at the Penn State Milton S. Hershey Medical Center, discusses two hot topics at RSNA 2023.
Jamie Bourque, MD, spoke to Cardiovascular Business about the growing number of ways FDG-PET scans are being used in cardiology. This includes evaluating inflammation, tracking EP device infections and much more.
Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."
Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.
There were some concerns among researchers after one study suggested iFR may increase the risk of mortality. New data presented at TCT 2023, however, showed that the two technologies are linked to similar outcomes.
